OXBDF (Oxford BioMedica) Ending Cash Position: $129.7 Mil (As of Dec. 2025)


OXBDF Oxford BioMedica PLC OXBDF
72 GF Score
Price $7.99
GF Value $7.14
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Ending Cash Position?

Oxford BioMedica OXBDF 72 Ending Cash Position is $129.7 Mil as of Dec. 2025. GuruFocus rates OXBDF with a GF Score™ of 72/100 and a GF Value™ of $7.14 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Oxford BioMedica's Ending Cash Position for the quarter that ended in Dec. 2025 was $129.7 Mil.

Oxford BioMedica's quarterly Ending Cash Position declined from Dec. 2024 ($76.7 Mil) to Jun. 2025 ($73.1 Mil) but then increased from Jun. 2025 ($73.1 Mil) to Dec. 2025 ($129.7 Mil).

Oxford BioMedica's annual Ending Cash Position declined from Dec. 2023 ($131.3 Mil) to Dec. 2024 ($76.7 Mil) but then increased from Dec. 2024 ($76.7 Mil) to Dec. 2025 ($129.7 Mil).

Oxford BioMedica Ending Cash Position Related Terms

Oxford BioMedica Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica Ending Cash Position Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 144.87 172.09 131.29 76.68 129.70

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.29 103.57 76.68 73.10 129.70
OXBDF
72GF Score
Oxford BioMedica PLC OXBDF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Oxford BioMedica's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=81.19+48.507
=129.7

Oxford BioMedica's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=72.124+57.573
=129.7

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $129.7 Mil mean?
Oxford BioMedica (OXBDF) has a Ending Cash Position of $129.7 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Oxford BioMedica and its competitors.
Is Oxford BioMedica's Ending Cash Position too high?
Oxford BioMedica's current Ending Cash Position is $129.7 Mil. Overall, Oxford BioMedica has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Ending Cash Position compare to VRTX and REGN?
Oxford BioMedica's Ending Cash Position of $129.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current Ending Cash Position is $129.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.14, compared to a current price of $7.99 — trading 11.9% above its estimated fair value. The current Ending Cash Position is $129.7 Mil. Oxford BioMedica's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Ending Cash Position is $129.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (OXBDF) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of $7.99 is trading 11.9% above its estimated GF Value™ of $7.14. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for OXBDF:

  • Ending Cash Position: $129.7 Mil
  • GF Value™: $7.14 vs. price of $7.99 (11.9% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBl:UKOXB:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
72GF Score

Get the complete analysis for OXBDF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.99
Price
$7.14
GF Value